View Item 

Show simple item record

Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline
dc.contributor.authorPeres, E.en_US
dc.contributor.authorKhaled, Y.en_US
dc.contributor.authorKrijanovski, O. I.en_US
dc.contributor.authorMineishi, S.en_US
dc.contributor.authorLevine, John E.en_US
dc.contributor.authorKaul, D. R.en_US
dc.contributor.authorRiddell, Jamesen_US
dc.date.accessioned2010-06-01T21:01:25Z
dc.date.available2010-06-01T21:01:25Z
dc.date.issued2009-02en_US
dc.identifier.citationPeres, E.; Khaled, Y.; Krijanovski, O.I.; Mineishi, S.; Levine, J.E.; Kaul, D.R.; Riddell, J. (2009). " Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline." Transplant Infectious Disease 11(1): 57-63. <http://hdl.handle.net/2027.42/74115>en_US
dc.identifier.issn1398-2273en_US
dc.identifier.issn1399-3062en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74115
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18983415&dopt=citationen_US
dc.description.abstractWe present a case of progressive Mycobacterium chelonae ssp. chelonae necrotizing pneumonia after hematopoietic stem cell transplantation (HSCT) in the presence of chronic graft-versus-host disease. The patient failed to respond to standard combination therapy with multiple agents and developed resistance to most drugs over the course of treatment. Tigecycline, a new glycylcycline antimicrobial agent with in vitro activity against M. chelonae , was then used with a clinical response to treatment. To our knowledge, this is the first reported case demonstrating tigecycline to have a degree of clinical effectiveness to treat refractory pulmonary infection with M. chelonae in an HSCT recipient.en_US
dc.format.extent419421 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2009 John Wiley & Sons A/Sen_US
dc.subject.otherStem Cell Transplanten_US
dc.subject.otherNon-tuberculous Mycobacteriumen_US
dc.subject.otherPneumoniaen_US
dc.subject.otherTigecyclineen_US
dc.subject.otherMycobacterium Chelonaeen_US
dc.titleMycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecyclineen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumBlood and Marrow Transplant Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA , anden_US
dc.contributor.affiliationumDivision of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USAen_US
dc.identifier.pmid18983415en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74115/1/j.1399-3062.2008.00351.x.pdf
dc.identifier.doi10.1111/j.1399-3062.2008.00351.xen_US
dc.identifier.sourceTransplant Infectious Diseaseen_US
dc.identifier.citedreferenceWeinstock D, Feinstein M, Sepkowitz K, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1015 – 1021.en_US
dc.identifier.citedreferenceRoy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant 1997; 19: 467 – 470.en_US
dc.identifier.citedreferenceGaviria J, Garcia P, Garrido S, Corey L, Boeckh M. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 2000; 6: 361 – 369.en_US
dc.identifier.citedreferenceCordonnier C, Martino R, Trabasso P, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis 2002; 38: 1229 – 1236.en_US
dc.identifier.citedreferenceField S, Cowie R. Lung disease due to the more common nontuberculous mycobacteria. Chest 2006; 129: 1653 – 1672.en_US
dc.identifier.citedreferenceJacobson K, Garcia R, Libshitz H, et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis 1998; 17: 615 – 621.en_US
dc.identifier.citedreferenceKourbeti I, Maslow M. Nontuberculous mycobacterial infections of the lung. Curr Infect Dis Rep 2000; 2: 193 – 200.en_US
dc.identifier.citedreferenceGriffith D, Aksamit T, Brown-Elliott B, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367 – 416.en_US
dc.identifier.citedreferenceFalkingham J 3rd. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002; 23: 529 – 551.en_US
dc.identifier.citedreferenceAu W, Cheng V, Ho P, et al. Nontuberculous mycobacterial infections in Chinese hematopoietic stem cell transplantation recipients. Bone Marrow Transplant 2003; 32: 709 – 714.en_US
dc.identifier.citedreferenceKurzrock R, Zander A, Vellekoop L, Kanojia M, Luna M, Dicke K. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med 1984; 77: 35 – 40.en_US
dc.identifier.citedreferenceNavari R, Sullivan K, Springmeyer S, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983; 36: 509 – 513.en_US
dc.identifier.citedreferenceDoucette K, Fishman J. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38: 1428 – 1439.en_US
dc.identifier.citedreferenceBodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008; 14: 390 – 396.en_US
dc.identifier.citedreferenceHazelton T, Newell J Jr, Cook J, Huitt G, Lynch D. CT findings in 14 patients with Mycobacterium chelonae pulmonary infection. Am J Roentgenol 2000; 175: 413 – 416.en_US
dc.identifier.citedreferenceDe Groote M, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006; 42: 1756 – 1763.en_US
dc.identifier.citedreference17.  NCCLS. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomyctes; approved standard. NCCLS 2003; M24 A.en_US
dc.identifier.citedreferenceTartaglione T. Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. Clin Ther 1997; 19: 626 – 638.en_US
dc.identifier.citedreferenceVemulapalli R, Cantey J, Steed L, Knapp T, Thielman N. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001; 43: 163 – 168.en_US
dc.identifier.citedreferenceBrown-Elliott B, Wallace R Jr, Blinkhorn R, Crist C, Mann L. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001; 33: 1433 – 1434.en_US
dc.identifier.citedreferenceWallace R Jr, Brown-Elliott B, Ward S, Crist C, Mann L, Wilson R. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45: 764 – 767.en_US
dc.identifier.citedreferenceWallace R Jr, Brown-Elliott B, Crist C, Mann L, Wilson R. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164 – 3167.en_US
dc.identifier.citedreference23.  Wyeth Pharmaceuticals. Tigecycline package insert (data on file).en_US
dc.identifier.citedreferenceTesta R, Petersen P, Jacobus N, Sum P-E, Lee V, Tally F. In vitro and in vivo antibacterial activities of the glycylcycline class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993; 37: 2270 – 2277.en_US
dc.identifier.citedreferencede Silva T, Cope A, Goepel J, Greig J. The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection. J Infect 2007; 54: e207 – e210.en_US
dc.identifier.citedreferenceMarshall S. Technology insight: ECP for the treatment of GvHD – can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3: 302 – 314.en_US
dc.identifier.citedreferenceAdams L, Gillis T, Hwang D, Krahenbuhl J. Effects of essential fatty acid deficiency on prostaglandin E2 production and cell-mediated immunity in a mouse model of leprosy. Infect Immun 1997; 65: 1152 – 1157.en_US
dc.identifier.citedreferenceBahr G, Rook G, Stanford J. Prostaglandin-dependent regulation of in vitro proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy. Clin Exp Immunol 1981; 45: 646 – 653.en_US
dc.identifier.citedreferenceVenkataprasad N, Shiratsuchi H, Johnson J, Ellner J. Induction of prostaglandin E2 by human monocytes infected with Mycobacterium avium complex – modulation of cytokine expression. J Infect Dis 1996; 174: 806 – 811.en_US
dc.identifier.citedreferenceSingh N, Yu V. Successful treatment of pulmonary infection due to Mycobacterium chelonae: case report and review. Clin Infect Dis 1992; 14: 156 – 161.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-3062.2008.00351.x.pdf
Size:
409.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.